Molecular and Cellular Pathology

British Journal of Cancer (2002) 87, 1281–1286. doi:10.1038/sj.bjc.6600624 www.bjcancer.com
Published online 12 November 2002

Expression of S100A4, E-cadherin, alpha- and bold beta-catenin in breast cancer biopsies

K B Pedersen1, J M Nesland2, Ø Fodstad1 and G M Mælandsmo1

  1. 1Department of Tumour Biology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway
  2. 2Department of Pathology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway

Correspondence: G M Mælandsmo, E-mail: g.m.malandsmo@labmed.uio.no

Received 24 April 2002; Revised 18 August 2002; Accepted 4 September 2002.

Top

Abstract

In 66 breast cancer biopsies, the expression of the Ca2+-binding protein S100A4, E-cadherin, alpha- and beta-catenin was examined by immunohistochemistry, and the results were related to clinical and pathological parameters. High levels of S100A4 were found to significantly correlate with histological grade (P=0.030) and loss of oestrogen receptor (P=0.046), but not to the time interval between surgery and development of distant metastasis (P=0.51) or to patient survival (P=0.89). Loss of E-cadherin expression, associated with altered cell–cell adhesion, showed a highly significant association to overall survival (P=0.020) and metastasis-free period (P=0.0052). In multivariate analysis, only lymph node involvement was a more significant predictor of patient demise. No association was found between expression of S100A4 and any single member of the cadherin–catenin complex, but a trend (P=0.053) towards reduced expression of one or several of these proteins and S100A4 immunoreactivity was observed. In conclusion, although our results suggest an association between S100A4 expression and an aggressive tumour phenotype, no relationship to overall survival was found. Deregulation of E-cadherin expression, however, was of high prognostic significance.

Keywords:

S100A4, mts1, calcium-binding protein, E-cadherin, immunohistochemistry, prognostic factor